Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varoglutamstat - Vivoryon Therapeutics

Next Previous
Drug Profile

Varoglutamstat - Vivoryon Therapeutics

Alternative Names: PQ-912; SIM 0408; SIM-0801

Latest Information Update: 07 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Probiodrug
  • Developer University of California, San Diego; Vivoryon Therapeutics
  • Class Anti-inflammatories; Antidementias; Benzimidazoles; Imidazolidines; Neuroprotectants; Small molecules
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Preclinical Inflammation
  • Phase Unknown Renal failure
  • Discontinued Alzheimer's disease; Huntington's disease

Most Recent Events

  • 27 May 2025 The United States Patent and Trademark Office (USPTO) has granted an additional patent for varoglutamstat
  • 14 May 2025 Investigation in Renal failure (Combination therapy) in Germany (unspecified route) prior to April 2025
  • 29 Apr 2025 Vivoryon receives a notice of allowance for the varoglutamstat COM patent application which was filed in the US following the completion of an accelerated examination process

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top